We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Amonafide in Combination With Cytarabine in Secondary AML

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00273884
First Posted: January 9, 2006
Last Update Posted: February 19, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Xanthus Pharmaceuticals, Inc.
  Purpose
This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.

Condition Intervention Phase
Acute Myeloid Leukemia Drug: Amonafide L-Malate Drug: Cytarabine Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Open-Label Study of Amonafide L-Malate in Combination With Cytarabine in Subjects With Secondary Acute Myeloid Leukemia (AML)

Resource links provided by NLM:


Further study details as provided by Xanthus Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • - To determine the rate of complete remission with or without complete hematopoietic recovery (CR + CRi).

Secondary Outcome Measures:
  • Determine the median duration of complete remission with or without complete hematopoietic recovery (CR or CRi)
  • Determine the proportion of subjects remaining in complete remission (CR +CRi) at 6 months, at 12 months and at 18 months
  • Determine the median duration of overall survival (OS)
  • Correlate clinical responses and duration of responses with specific cytogenetic abnormalities
  • Define the population pharmacokinetic (PK) profile of amonafide and its metabolites when administered as an intravenous infusion daily x 5 days in combination with a standard-dose of cytarabine
  • Define the safety profile and confirm the acceptability of amonafide and cytarabine
  • Correlate PK exposure of amonafide and acetylation of amonafide with safety and efficacy assessments in individual subjects

Estimated Enrollment: 80
Study Start Date: August 2005
Estimated Study Completion Date: April 2009
Detailed Description:

This is a two-stage, open-label, phase 2, multicenter study of amonafide L-malate in combination with standard-dose cytarabine in subjects with secondary AML.

Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML. In three phase I clinical trials, amonafide demonstrated anti-leukemic activity, both as monotherapy and in combination with cytarabine. This protocol is designed to further assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.

The duration of the study is approximately 42 months: enrollment approximately 18 months and subject duration up to 24 months

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologic diagnosis of AML (≥20% blasts of myeloid lineage in bone marrow), with FAB classification other than M3, secondary to either:

    1. Known and documented exposure to prior leukemogenic chemotherapy or radiotherapy, OR
    2. Diagnosis of MDS for ≥3 months prior to study entry (prior BM slides documenting MDS must be available for central pathology review).
  • Age 18 years or older.
  • ECOG performance status ≤2.
  • No prior induction chemotherapy for AML; at least 4 weeks since completion of prior chemotherapy for MDS. (Subjects with rapidly rising blast count may be enrolled within 4 weeks of prior cytotoxic chemotherapy).
  • Fertile and sexually active men and women must use effective contraception throughout study. Women of childbearing potential must have a negative pregnancy test.
  • LVEF ≥50% by MUGA or ECHO.
  • Adequate renal function: serum creatinine ≤1.5 x ULN.
  • Adequate hepatic function: total serum bilirubin ≤1.5 x ULN as well as serum AST and ALT ≤1.5 x ULN.
  • Subject must be able to participate fully in all aspects of the trial.
  • Subject must give voluntary, written consent and HIPAA authorization (US only).

Exclusion Criteria:

  • Histologic diagnosis of FAB M3 AML (acute promyelocytic leukemia).
  • Clinically active CNS leukemia.
  • Known to be HIV positive.
  • Prior induction chemotherapy for AML.
  • Known active hepatitis B or C or other active liver disease.
  • Any major surgery or radiation therapy within 4 weeks prior to study entry.
  • Prior cytotoxic chemotherapy within 4 weeks prior to study entry.(Subjects with rapidly rising blast count may be enrolled within 4 weeks of prior cytotoxic chemotherapy).
  • Persistent chronic non-hematologic toxicity from prior chemotherapy (other than alopecia) that is > than grade 1.
  • Serious concomitant illness (e.g., active pulmonary infection, unstable angina or myocardial infarction within 3 months of study entry, congestive heart failure ≥AHA class 2, stroke within 3 months prior to study entry, uncontrolled hypertension, uncontrolled diabetes, actively bleeding gastric ulcer, etc.).
  • Women who are pregnant or lactating.
  • History of clinically significant allergic reactions attributed to compounds similar to amonafide or cytarabine.
  • Prior enrollment on this trial.
  • Any other known condition (familial, sociological, or geographic) or behavior (including substance abuse, psychological or psychiatric illness), which in the investigator's opinion would make the subject a poor candidate for this trial.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273884


  Show 21 Study Locations
Sponsors and Collaborators
Xanthus Pharmaceuticals, Inc.
Investigators
Principal Investigator: Steven Allen, MD North Shore Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00273884     History of Changes
Other Study ID Numbers: 0001A3-200-GL
First Submitted: January 5, 2006
First Posted: January 9, 2006
Last Update Posted: February 19, 2007
Last Verified: February 2007

Keywords provided by Xanthus Pharmaceuticals, Inc.:
AML
Secondary AML
Leukemia

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Cytarabine
Amonafide
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Enzyme Inhibitors